DNA Alterations Identified Occur Earliest in Lung Cancer Development
By LabMedica International staff writers Posted on 30 Sep 2015 |
Lungs resected for adenocarcinomas often harbor minute discrete foci of cytologically atypical pneumocyte proliferations designated as atypical adenomatous hyperplasia (AAH), which may represent an initial step in the progression to adenocarcinoma in situ (AIS).
DNA alterations in the tissue and blood of people with precancerous and cancerous lung lesions has been identified in what it believes are among the very earliest "premalignant" genetic changes that mark the potential onset of the most common and deadliest form of disease.
Scientists at Johns Hopkins University School of Medicine (Baltimore, MD, USA) collected retrospectively formalin-fixed, paraffin-embedded (FFPE) lung cancer specimens harboring multiple AAH lesions and AIS or minimally invasive adenocarcinoma (MIA) tumors. DNA was extracted from 25 distinct AAHs incidentally discovered in the lung resection specimens from six patients with invasive adenocarcinoma. Samples from AIS and MIA tumors extracted from five patients each were collected from different zones of histologic progression within the same lesion. Three or four histologically different zones were collected from each AIS and MIA samples respectively.
DNA was extracted using standard protocols and quantified with the Nanodrop system (Thermo Scientific; Wilmington, DE, USA). The CancerSelect-R panel was used to analyze the regions of 125 well-characterized cancer genes to identify tumor-specific (somatic) mutations, copy number changes and translocations. Paired-end sequencing, resulting in 150 bases from each end of the fragments, was performed using a MiSeq System (Illumina; San Diego, CA, USA). All droplet digital polymerase chain reactions (ddPCR) assays used in the study were designed and optimized to work in the ddPCR system by Bio-Rad (Hercules, CA, USA).
The team found that V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), tumor protein p53 (TP53) and epidermal growth factor receptor (EGFR) mutations are indicators of malignant transition. Utilizing droplet digital PCR, they found alterations associated with early neoplasms in paired circulating DNA. When the team further explored different regions within the same lesion, they found genetic differences even within the same lesion. Mutations associated with good and poor prognosis or responses to therapy were seen in different regions of the same tumor, highlighting the limitations of single biopsies commonly used to decide patients' therapies.
David Sidransky, MD, a professor of oncology and pathology and senior author of the study said, “This study takes detection to a whole new level in terms of size of the lesion. I'm not aware that circulating DNA from precancerous lesions this small has ever been identified before.” As they detected the mutations in the fluids, even mutations found in only one specific zone of a lesion, Prof. Sidransky added, “That this finding may indicate that a blood or sputum test could better represent the overall composition of a tumor than a single biopsy sample.” The study was published on September 16, 2015, in the journal Nature Communications.
Related Links:
Johns Hopkins University School of Medicine
Nanodrop
Illumina
DNA alterations in the tissue and blood of people with precancerous and cancerous lung lesions has been identified in what it believes are among the very earliest "premalignant" genetic changes that mark the potential onset of the most common and deadliest form of disease.
Scientists at Johns Hopkins University School of Medicine (Baltimore, MD, USA) collected retrospectively formalin-fixed, paraffin-embedded (FFPE) lung cancer specimens harboring multiple AAH lesions and AIS or minimally invasive adenocarcinoma (MIA) tumors. DNA was extracted from 25 distinct AAHs incidentally discovered in the lung resection specimens from six patients with invasive adenocarcinoma. Samples from AIS and MIA tumors extracted from five patients each were collected from different zones of histologic progression within the same lesion. Three or four histologically different zones were collected from each AIS and MIA samples respectively.
DNA was extracted using standard protocols and quantified with the Nanodrop system (Thermo Scientific; Wilmington, DE, USA). The CancerSelect-R panel was used to analyze the regions of 125 well-characterized cancer genes to identify tumor-specific (somatic) mutations, copy number changes and translocations. Paired-end sequencing, resulting in 150 bases from each end of the fragments, was performed using a MiSeq System (Illumina; San Diego, CA, USA). All droplet digital polymerase chain reactions (ddPCR) assays used in the study were designed and optimized to work in the ddPCR system by Bio-Rad (Hercules, CA, USA).
The team found that V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), tumor protein p53 (TP53) and epidermal growth factor receptor (EGFR) mutations are indicators of malignant transition. Utilizing droplet digital PCR, they found alterations associated with early neoplasms in paired circulating DNA. When the team further explored different regions within the same lesion, they found genetic differences even within the same lesion. Mutations associated with good and poor prognosis or responses to therapy were seen in different regions of the same tumor, highlighting the limitations of single biopsies commonly used to decide patients' therapies.
David Sidransky, MD, a professor of oncology and pathology and senior author of the study said, “This study takes detection to a whole new level in terms of size of the lesion. I'm not aware that circulating DNA from precancerous lesions this small has ever been identified before.” As they detected the mutations in the fluids, even mutations found in only one specific zone of a lesion, Prof. Sidransky added, “That this finding may indicate that a blood or sputum test could better represent the overall composition of a tumor than a single biopsy sample.” The study was published on September 16, 2015, in the journal Nature Communications.
Related Links:
Johns Hopkins University School of Medicine
Nanodrop
Illumina
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans